 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...212213214215216217218219220221222...235236» |
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: MOMA: Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2014
P2, N=222, Recruiting, Sponsor: Azienda Ospedaliero, Universitaria Pisana
- | crenolanib (ARO-002) / AROG
New P1 trial, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Oct 22, 2014
P1, N=24, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- 5-fluorouracil / Generic mfg.
New P1 trial, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Oct 22, 2014
P1, N=20, Not yet recruiting, Sponsor: Virginia Commonwealth University
- | Avastin (bevacizumab) / Roche
Enrollment closed: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Oct 22, 2014
P1/2, N=45, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting
- |||| pentamidine oral (VLX103) / Odan Labs
Trial completion, Metastases: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (clinicaltrials.gov) - Oct 22, 2014
P2, N=53, Completed, Sponsor: Oncozyme Pharma Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion: Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia (clinicaltrials.gov) - Oct 22, 2014
P2, N=105, Completed, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Oct 20, 2014
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jul 2018
- |||| pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Enrollment open, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 20, 2014
P1/2, N=172, Recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Dec 2014 --> Jul 2018 Suspended --> Recruiting
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Oct 17, 2014
P2, N=57, Recruiting, Sponsor: Sanofi
Suspended --> Recruiting Trial primary completion date: Jan 2016 --> Sep 2016
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2016 --> Sep 2016 Trial primary completion date: Dec 2017 --> Nov 2016
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Oct 17, 2014
P1, N=45, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Dec 2017 --> Nov 2016 Trial primary completion date: Mar 2015 --> Mar 2016
- |||||| onartuzumab (RG3638) / Roche
Enrollment open, Enrollment change, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Oct 17, 2014
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2015 --> Mar 2016 Active, not recruiting --> Recruiting | N=564 --> 800
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Metastases: AFLAME: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (clinicaltrials.gov) - Oct 17, 2014
P3, N=330, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Recruiting | N=564 --> 800 Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 17, 2014
P4, N=127, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=245, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012
- Avastin (bevacizumab) / Roche
Trial completion: DCE-MRI PET Bevacizumab Study in Rectal Cancer (clinicaltrials.gov) - Oct 15, 2014
P2, N=30, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012 Recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Oct 11, 2014
P2, N=39, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed Trial primary completion date: Dec 2014 --> Jul 2016
- Hepacid (pegargiminase) / Polaris Pharma
Trial initiation date, Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 11, 2014
P1, N=22, Not yet recruiting, Sponsor: Polaris Group
Trial primary completion date: Dec 2014 --> Jul 2016 Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Jul 2015 --> Nov 2015
- | Enrollment change, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Oct 11, 2014
P2, N=21, Active, not recruiting, Sponsor: University of California, San Francisco
Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Jul 2015 --> Nov 2015 N=45 --> 21
- | Erbitux (cetuximab) / Eli Lilly
Phase classification, Metastases: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (clinicaltrials.gov) - Oct 11, 2014
P2, N=238, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=45 --> 21 Phase classification: P3 --> P2
- Avastin (bevacizumab) / Roche
Metastases: Escalated Dose of Irinotecan in mCRC (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=320, Recruiting, Sponsor: Jaw-Yuan Wang, MD, PhD
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
P3 data: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P3, N=1400, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P3 --> P2 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2019 --> Feb 2022
- leucovorin calcium / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Oct 10, 2014
P1, N=39, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2019 --> Feb 2022 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Oct 2014 | Trial primary completion date: Apr 2019 --> Oct 2018
- Enrollment open: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis (clinicaltrials.gov) - Oct 10, 2014
P2, N=65, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Oct 2014 | Trial primary completion date: Apr 2019 --> Oct 2018 Suspended --> Recruiting
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment open, Trial primary completion date: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Oct 4, 2014
P1/2, N=6, Recruiting, Sponsor: Isofol Medical AB
Suspended --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Trial primary completion date, Metastases: A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer (clinicaltrials.gov) - Oct 2, 2014
P3, N=175, Recruiting, Sponsor: AHS Cancer Control Alberta
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Jun 2014 --> Apr 2015
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Oct 2, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Apr 2015 Trial primary completion date: Aug 2014 --> Jan 2015
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Sep 30, 2014
P2, N=57, Recruiting, Sponsor: Sanofi
Trial primary completion date: Aug 2014 --> Jan 2015 Trial primary completion date: Apr 2015 --> Jan 2016
- || oxaliplatin / Generic mfg.
New P3 trial: Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer (clinicaltrials.gov) - Sep 29, 2014
P3, N=188, Recruiting, Sponsor: Yuhong Li
- | Vectibix (panitumumab) / Amgen
Trial completion, Trial primary completion date: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only (clinicaltrials.gov) - Sep 29, 2014
P2, N=15, Completed, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Apr 2015 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Sep 28, 2014
P2, N=50, Recruiting, Sponsor: howard safran
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- Trial primary completion date: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=24, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Jun 2015
- Avastin (bevacizumab) / Roche, GI-4000 / ImmunityBio
Enrollment change, Trial termination, Metastases: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI (clinicaltrials.gov) - Sep 28, 2014
P2, N=11, Terminated, Sponsor: Georgetown University
Trial primary completion date: Mar 2014 --> Jun 2015 N=52 --> 11 | Active, not recruiting --> Terminated; Poor accrual rate
- erlotinib / Generic mfg.
Enrollment change, Trial termination, Metastases: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 28, 2014
P2, N=16, Terminated, Sponsor: OHSU Knight Cancer Institute
N=52 --> 11 | Active, not recruiting --> Terminated; Poor accrual rate N=70 --> 16 | Active, not recruiting --> Terminated; Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed: BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study (clinicaltrials.gov) - Sep 28, 2014
P1, N=35, Active, not recruiting, Sponsor: Brown University
N=70 --> 16 | Active, not recruiting --> Terminated; Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis. Recruiting --> Active, not recruiting
- bortezomib / Generic mfg.
Enrollment closed, Enrollment change, Combination therapy: AALL07P1: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=151, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting | N=60 --> 151
- | pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Trial suspension, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 22, 2014
P1/2, N=172, Suspended, Sponsor: Southwest Oncology Group
Suspended --> Active, not recruiting | N=60 --> 151 Recruiting --> Suspended
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
P3 data: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P3, N=1400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Initiation date: Apr 2014 --> Oct 2014
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Be TRI: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Sep 22, 2014
P2, N=65, Recruiting, Sponsor: EPS Corporation
- | Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Roche
Trial completion, Metastases: Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P2, N=97, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2014 --> Oct 2014 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (clinicaltrials.gov) - Sep 19, 2014
P2/3, N=252, Recruiting, Sponsor: Centre Georges Francois Leclerc
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Oct 2014
- Avastin (bevacizumab) / Roche
Trial primary completion date: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2014
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2014 --> Oct 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- | New P2 trial: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Sep 19, 2014
P2, N=112, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2014
P2, N=75, Recruiting, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- | brivanib alaninate (BMS-582664) / ZAI Lab
Trial completion, Enrollment change, Combination therapy, Metastases: Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) (clinicaltrials.gov) - Sep 16, 2014
P1, N=49, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=72 --> 49
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 15, 2014
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed | N=72 --> 49 Trial primary completion date: Oct 2014 --> Oct 2015
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Sep 15, 2014
P2, N=44, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- DC-CIK / Hornetcorn Biotech
Enrollment open: Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer (clinicaltrials.gov) - Sep 12, 2014
P2, N=40, Recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- DC-CIK / Hornetcorn Biotech
Enrollment open, Surgery: Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 12, 2014
P2, N=60, Recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Trial completion: CALGB-50202: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma (clinicaltrials.gov) - Sep 12, 2014
P2, N=47, Completed, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Recruiting Active, not recruiting --> Completed